Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sinovac Biotech Ltd.    SVA   AGP8696W1045

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

China's Sinovac vaccine to be included in Brazil's immunization program, governors say

10/20/2020 | 03:20pm EST

BRASILIA, Oct 20 (Reuters) - The Brazilian government will include China's Sinovac vaccine against COVID-19 in its national immunization program, state governors said on Tuesday after a meeting with the country's health minister, in addition to the vaccine developed by AstraZeneca and Oxford University.

Sao Paulo governor Joao Doria said the federal government has agreed to buy 46 million doses of the Sinovac vaccine and that national vaccination could begin in January 2021, which could be one of the first immunization efforts against coronavirus in the world.

(Reporting by Anthony Boadle; Editing by Christian Plumb)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
DIAGNOSTICOS DA AMÉRICA S.A. 0.50% 60 End-of-day quote.3.97%
MODERNA, INC. 10.78% 109.18 Delayed Quote.458.18%
SINOPHARM GROUP CO., LTD. 0.00% 19.74 End-of-day quote.-30.62%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
All news about SINOVAC BIOTECH LTD.
11/23Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - offi..
RE
11/23Sao Paulo expects regulator approval for Sinovac vaccine by January
RE
11/23Q&A : Where are we in the COVID-19 vaccine race?
RE
11/20SINOVAC BIOTECH : Pfizer eyes rapid COVID-19 vaccine roll-out in Latam after U.S..
RE
11/20Britain asks regulator to assess Pfizer vaccine for suitability
RE
11/20UK asks regulator to assess Pfizer vaccine for suitability
RE
11/20Sinovac may get Phase III trial results of COVID-19 vaccine by December, exec..
RE
11/17Brazil to receive China's Sinovac COVID-19 vaccine, eyes Pfizer candidate
RE
11/17Sinovac's COVID-19 vaccine induces quick immune response - study
RE
11/17Sinovac's COVID-19 vaccine induces quick immune response - study
RE
More news
Financials (USD)
Sales 2019 246 M - -
Net income 2019 44,9 M - -
Net cash 2019 183 M - -
P/E ratio 2019 17,8x
Yield 2019 -
Capitalization 640 M 640 M -
EV / Sales 2018 1,38x
EV / Sales 2019 1,86x
Nbr of Employees 910
Free-Float 50,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang Chief Financial Officer & Vice President
Qiang Gao Vice President-Research & Development
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.-6.77%640
CSL LIMITED11.34%103 950
SAMSUNG BIOLOGICS CO.,LTD.84.53%48 002
BIOGEN INC.-18.53%37 201
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.138.48%29 065
ALEXION PHARMACEUTICALS, INC.13.83%26 903